Biotech News

Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

Tango Therapeutics (TNGX)Tango TherapeuticsEarnings

Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L pancreatic cancer; combination was generally well-tolerated

Related news

Tango Therapeutics

Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen...

Recent company news

Stock data

Close
22.71 USD
Market cap
3.11B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States